This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)

This study has been completed.
Collaborative Study Group (CSG)
Information provided by (Responsible Party):
Keryx Biopharmaceuticals Identifier:
First received: March 27, 2008
Last updated: March 3, 2017
Last verified: March 2017
Results First Received: October 4, 2014  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: No masking;   Primary Purpose: Treatment
Conditions: Hyperphosphatemia
End-stage Renal Disease
Intervention: Drug: ferric citrate

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
KRX-0502 Ferric Citrate

Participant Flow:   Overall Study
Start Dose 4.5 g/Day   34 
Start Dose 6 g/Day   21 
Adverse Event                6 
unable to swallow tablets                1 

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.

Reporting Groups
KRX-0502 Subjects in this group were initiated on a dose of 4.5 g/day (34 subjects) or 6.0 g/day (21 subjects) of KRX-0502 (ferric citrate)

Baseline Measures
Overall Participants Analyzed 
[Units: Participants]
[Units: Years]
Mean (Standard Deviation)
 53.46  (11.48) 
Sex: Female, Male 
[Units: Participants]
Count of Participants
Female      23  41.8% 
Male      32  58.2% 
Region of Enrollment 
[Units: Participants]
United States   50 
Puerto Rico   5 

  Outcome Measures

1.  Primary:   The Difference in Serum Phosphorus Between Baseline (Day 0) and End of Treatment (Day 28)   [ Time Frame: 28 days ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Medical Information
Organization: Keryx Biopharmaceuticals Inc
phone: 1-844-44-KERYX (1-844-445-3799

Responsible Party: Keryx Biopharmaceuticals Identifier: NCT00648167     History of Changes
Other Study ID Numbers: KRX-0502-201
Study First Received: March 27, 2008
Results First Received: October 4, 2014
Last Updated: March 3, 2017